Home » Topics » Science » Drug design, drug delivery and technologies

Drug design, drug delivery and technologies
RSS

RPR Gencell and IntraImmune Therapies enter drug development agreement

June 21, 1996

Megabios issued worldwide license to lipid-DNA complexes

June 21, 1996

Drug development agreement reached by Megabios and Pfizer

June 21, 1996

HemaSure/American Red Cross Biomedical Services alliance

June 14, 1996

Exelixis acquires rights to P Element technology

June 14, 1996

Bayer/CV Therapeutics antiinflammatory drug agreement

June 14, 1996

Bristol-Myers Squibb/Garvan Institute of Medical Research collaboration

June 14, 1996

Ingenex granted phase II SBIR grant

June 14, 1996

Neoprobe and Dow enter licensing agreement

June 7, 1996

Research agreement: TCPI and the University of Kansas

June 7, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...